| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/21/2002 | WO2002022576A2 3-substituted indole carbohydrazides useful as cell proliferation and angiogenesis inhibitors |
| 03/21/2002 | WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | WO2002022562A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022176A1 Method of modulating neovascularization |
| 03/21/2002 | WO2002022175A2 Method and composition for treating tumors by selective induction of apoptosis |
| 03/21/2002 | WO2002022169A2 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022164A1 Composition comprising immunogenic microparticles |
| 03/21/2002 | WO2002022161A2 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | WO2002022160A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | WO2002022159A1 Thionin as an antineoplastic and immunostimulant |
| 03/21/2002 | WO2002022151A2 Use of glp-1 and flp-2 peptides for treatment of bone disorders |
| 03/21/2002 | WO2002022150A2 Medicament containing activated antithrombin iii |
| 03/21/2002 | WO2002022145A2 Components of canola for the treatment of cancer |
| 03/21/2002 | WO2002022140A1 Homeostasis-maintaining agents |
| 03/21/2002 | WO2002022134A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | WO2002022130A2 Means for regulating immune defences |
| 03/21/2002 | WO2002022123A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/21/2002 | WO2002022000A2 Targeted alpha particle therapy using actinium-225 conjugates |
| 03/21/2002 | WO2002021996A2 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 03/21/2002 | WO2001096388A8 Compositions and methods for the therapy and diagnosis of colon cancer |
| 03/21/2002 | WO2001087982A3 Immunotoxin fusion proteins and means for expression thereof |
| 03/21/2002 | WO2001087846A3 Tricyclic pyrazole derivatives as protein kinase inhibitors |
| 03/21/2002 | WO2001087039A3 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2 |
| 03/21/2002 | WO2001083457A3 Benzimidazole-2-carbamates and their use in cancer treatment |
| 03/21/2002 | WO2001078702A3 Methods and compositions for modulating alpha adrenergic receptor activity |
| 03/21/2002 | WO2001077376A8 Diagnosis of diseases associated with metastasis |
| 03/21/2002 | WO2001077303A3 Human ovarian mesothelial cells and methods of isolation and uses thereof |
| 03/21/2002 | WO2001077164A8 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis |
| 03/21/2002 | WO2001074379A3 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 03/21/2002 | WO2001072840A3 Isolated human g-protein coupled receptors of the mas proto-oncogene subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 03/21/2002 | WO2001070694A8 Amorphous torasemide modification |
| 03/21/2002 | WO2001068859A3 Il-17 receptor like molecules and uses thereof |
| 03/21/2002 | WO2001068034A3 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions |
| 03/21/2002 | WO2001066099A3 Use of quinazoline derivatives as angiogenesis inhibitors |
| 03/21/2002 | WO2001064837A3 β NETRIN AND USES THEREOF |
| 03/21/2002 | WO2001064252A3 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| 03/21/2002 | WO2001064218A3 Farnesyl protein transferase inhibitor combinations |
| 03/21/2002 | WO2001064198A3 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 03/21/2002 | WO2001064197A3 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 03/21/2002 | WO2001064196A3 Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| 03/21/2002 | WO2001064195A3 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| 03/21/2002 | WO2001064165A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001062942A3 MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS |
| 03/21/2002 | WO2001062905A3 Integrin antagonists |
| 03/21/2002 | WO2001062725A3 Methods and compositions for inhibiting angiogenesis |
| 03/21/2002 | WO2001060991A3 Human kinases |
| 03/21/2002 | WO2001060319A3 Polyhydroxylated benzene-containing compounds |
| 03/21/2002 | WO2001058954A3 Trade molecules and uses related thereto |
| 03/21/2002 | WO2001058934A3 Kahalalide f and related compounds |
| 03/21/2002 | WO2001056548A3 Liposomes composition produced by a dehydration-rehydration process |
| 03/21/2002 | WO2001055106A3 Novel melanocortin receptor agonists and antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001037779A3 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 03/21/2002 | WO2001035943A3 Dextrose and insulin fluid formulation for intravenous infusion |
| 03/21/2002 | WO2001034196A3 Mixture containing rare earths and use thereof |
| 03/21/2002 | WO2001034135A3 Oncolytic combinations for the treatment of cancer |
| 03/21/2002 | WO2001030375A3 Use of gdnf for treating corneal defects |
| 03/21/2002 | WO2001010199A9 A knockout mouse for the tumor suppressor gene anx7 |
| 03/21/2002 | US20020035737 Cloning pigs using donor nuclei from differentiated cells |
| 03/21/2002 | US20020035735 Reproducing and animal; obtain preferential embryonic cells, culture cells, transfer cells to primate, recover infant |
| 03/21/2002 | US20020035734 Binding protein for use in the treatment of neutropenia, infections and cancer |
| 03/21/2002 | US20020035325 Method for detecting lymphoid tissue in tumor progression |
| 03/21/2002 | US20020035264 Therapy for vision disorders |
| 03/21/2002 | US20020035262 7-hetero-bicyclo[2.2.1]-heptanes |
| 03/21/2002 | US20020035260 4-aza-steroids |
| 03/21/2002 | US20020035251 Antiproliferative agents |
| 03/21/2002 | US20020035243 Drug complexes |
| 03/21/2002 | US20020035240 Novel mammalian cell cycle protein |
| 03/21/2002 | US20020035161 O/W emulsions comprising micronized biologically active agents |
| 03/21/2002 | US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/21/2002 | US20020035118 Low molecular weight cell, bone marrow and immune stimulants |
| 03/21/2002 | US20020035114 Substituted dimeric compounds |
| 03/21/2002 | US20020035106 Use of potassium channel agonists for reducing fat food consumption |
| 03/21/2002 | US20020035102 Azetidine derivatives, their preparation and medicaments containing them |
| 03/21/2002 | US20020035098 Agents and methods for the prevention of initial onset and recurrence of existing cancers |
| 03/21/2002 | US20020035094 Substituted pyridine compounds and methods of use |
| 03/21/2002 | US20020035093 Methods for the administration of amifostine and related compounds |
| 03/21/2002 | US20020035092 Propanoic acid derivatives |
| 03/21/2002 | US20020035091 Administering thalidomide and irinotecan; avoiding adverse side effects associated with irinotecan |
| 03/21/2002 | US20020035090 Compositions and methods for the treatment of cancer |
| 03/21/2002 | US20020035077 Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| 03/21/2002 | US20020035065 Selective MMP inhibitors having reduced side-effects |
| 03/21/2002 | US20020034806 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| 03/21/2002 | US20020034803 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/21/2002 | US20020034787 Nucleotide sequences coding polypeptides for use in treatment of wounds, burns, ulcers, nervous system disorders and tumors |
| 03/21/2002 | US20020034777 Modulator of use in the diagnosis, prevention and treatment of inflammation, cancer and nervous system disorders; hypotensive agent |
| 03/21/2002 | US20020034758 Novel human genes and gene expressions products: II |
| 03/21/2002 | US20020034734 Vaccine composition for preventing or treating hepatitis C |
| 03/21/2002 | US20020034725 Sensitization of cells to radiation and and chemotherapy |
| 03/21/2002 | US20020034538 Liposomal benzoquinazolne thymidylate synthase inhibitor formulations |
| 03/21/2002 | US20020034537 For enhancing selective delivery of therapeutic, diagnostic and imaging agents to activated vascular sites |
| 03/21/2002 | US20020034534 Receptor loading dosage form containing therapeutic agent and extended-release dosage form containing therapeutic agent administered concurrently |
| 03/21/2002 | US20020034514 Administering microsphere of immunogens; enteric overcoatings |
| 03/21/2002 | US20020034393 Vector |
| 03/21/2002 | DE10138935A1 Synthetische Verbindungen vom Nicht-Mucintyp oder ihre mit einem Träger konjugierten Verbindungen Synthetic compounds from non-mucin or its conjugated with a carrier compounds |